EUROSCREEN - PRWeb Press Release Account Feed http://www.rsspad.com/rss2a/29375.xml EUROSCREEN - Press Releases en xml@emediawire.com xml@emediawire.com 30 Euroscreen Appoints Geert Cauwenbergh and Yves Ribeill as Directors http://www.prweb.com/releases/2008/07/prweb1093074.htm EUROSCREEN S.A. announced today that it has appointed Dr. Geert Cauwenbergh, former CEO of Barrier Therapeutics Inc. and Dr. Yves Ribeill, CEO of Scynexis, Inc., to its board of directors, adding significant, further depth and expertise to EUROSCREEN's board. (PRWeb Jul 14, 2008)

Read the full story at http://www.prweb.com/releases/2008/07/prweb1093074.htm

]]> http://www.prweb.com/releases/2008/07/prweb1093074.htm Euroscreen FAST: A fully Dedicated Business Unit for GPCR Screening Will Present its Expanded Services at SBS Meeting http://www.prweb.com/releases/2008/04/prweb782174.htm Michel Detheux, Ph.D., Director Euroscreen FAST Business Unit ,will present Euroscreen FAST capabilities and expertise at the 14th Annual Conference and Exhibition of the Society for Biomolecular Sciences (SBS Meeting) in St. Louis. (PRWeb Apr 1, 2008)

Read the full story at http://www.prweb.com/releases/2008/04/prweb782174.htm

]]> http://www.prweb.com/releases/2008/04/prweb782174.htm Euroscreen Wins Opposition Related to its CCR5 Patent Claims http://www.prweb.com/releases/2008/03/prweb716554.htm Euroscreen SA today announced its success in its patent battle against Progenics Inc. (PRWeb Mar 7, 2008)

Read the full story at http://www.prweb.com/releases/2008/03/prweb716554.htm

]]> http://www.prweb.com/releases/2008/03/prweb716554.htm Euroscreen Licenses CCR5 Patent Rights to AstraZeneca http://www.prweb.com/releases/2008/03/prweb674774.htm Euroscreen S.A. has completed a license agreement with AstraZeneca UK Ltd, for access to its worldwide portfolio of CCR5 patent rights. Financial details of the agreement were not disclosed. (PRWeb Mar 3, 2008)

Read the full story at http://www.prweb.com/releases/2008/03/prweb674774.htm

]]> http://www.prweb.com/releases/2008/03/prweb674774.htm Euroscreen Receives Patent Covering Methods to Identify Compounds That Bind to Chemerin Receptor http://www.prweb.com/releases/2008/02/prweb705063.htm Euroscreen has been awarded a US patent for uses of Chemerin receptor and its natural ligand, Chemerin; both implicated in the control of physiological and pathological inflammatory reactions. (PRWeb Feb 19, 2008)

Read the full story at http://www.prweb.com/releases/2008/02/prweb705063.htm

]]> http://www.prweb.com/releases/2008/02/prweb705063.htm Euroscreen Presents Proof-of-Concept Data for its Lead Candidate ESN-196, a CCR5 agonist for the Treatment of HIV http://www.prweb.com/releases/2008/02/prweb673464.htm Euroscreen SA today announced preclinical results for its CCR5 agonist, ESN-196, at the 15th Conference on Retroviruses and Opportunistic Infections held in Boston, MA.Data presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA. (PRWeb Feb 5, 2008)

Read the full story at http://www.prweb.com/releases/2008/02/prweb673464.htm

]]> http://www.prweb.com/releases/2008/02/prweb673464.htm Euroscreen Receives Key US Patent Covering Methods for Identifying Compounds Which Decrease HIV Entry Into Cells http://www.prweb.com/releases/2007/10/prweb562529.htm Brussels, Belgium. 23rd October 2007 - Euroscreen SA today announced that it was awarded a US patent that covers the use of CCR5 receptor in the HIV field. This new Euroscreen US patent (7,285,390) protects methods to single out compounds that decrease the HIV entry into target cells. (PRWeb Oct 23, 2007)

Read the full story at http://www.prweb.com/releases/2007/10/prweb562529.htm

]]> http://www.prweb.com/releases/2007/10/prweb562529.htm Euroscreen Receives Key US Patent Covering Screening Methods Using Human P2Y11 Purinergic Receptor http://www.prweb.com/releases/2007/09/prweb556345.htm Euroscreen SA today announced that it was awarded a US patent that covers the use of a G-Protein-Coupled Receptor (GPCR) known as the human P2Y11 receptor. (PRWeb Sep 27, 2007)

Read the full story at http://www.prweb.com/releases/2007/09/prweb556345.htm

]]> http://www.prweb.com/releases/2007/09/prweb556345.htm Euroscreen Licenses CCR5 Patent Rights to Boehringer Ingelheim http://www.prweb.com/releases/2007/09/prweb543164.htm Euroscreen S.A. has completed a license agreement with Boehringer Ingelheim, for access to the portfolio of CCR5 patent rights owned and licensed to Euroscreen. Financial details of the agreement were not disclosed. (PRWeb Sep 4, 2007)

Read the full story at http://www.prweb.com/releases/2007/09/prweb543164.htm

]]> http://www.prweb.com/releases/2007/09/prweb543164.htm Euroscreen SA Today Announced the Appointment of Graeme Fraser, Ph.D. as Director of Drug Discovery http://www.prweb.com/releases/2007/07/prweb539378.htm Euroscreen SA today announced the appointment of Graeme Fraser, Ph.D. as Director of Drug Discovery. (PRWeb Jul 16, 2007)

Read the full story at http://www.prweb.com/releases/2007/07/prweb539378.htm

]]> http://www.prweb.com/releases/2007/07/prweb539378.htm Euroscreen Announces the Completion of Research Agreement with GNF and Novartis http://www.prweb.com/releases/2007/03/prweb509196.htm Euroscreen and GNF will be engaged in research focused upon the development of therapeutic antibodies targeting G protein coupled receptors (GPCRs). Financial details of the agreement, and the specific GPCRs involved were not disclosed. (PRWeb Mar 23, 2007)

Read the full story at http://www.prweb.com/releases/2007/03/prweb509196.htm

]]> http://www.prweb.com/releases/2007/03/prweb509196.htm Euroscreen to Present at the BIO CEO & Investor Conference http://www.prweb.com/releases/2007/02/prweb502660.htm Euroscreen SA announced today that the company is scheduled to present at BIO CEO & Investor Conference on Wednesday, February 14th, 2007 at 2:15 p.m. in NYC. Jean Combalbert, Ph.D., Euroscreen's Chief Executive Officer, will provide a corporate overview of the company. This will be the company's first presentation since the €14 millions sale of its 12 year old products business to PerkinElmer, Inc. in January of this year. Following the deal, Euroscreen retained complete access and use of all of its previous reagents, procedures and patents for applications in their drug development and custom service businesses which are the focus of its future growth. (PRWeb Feb 7, 2007)

Read the full story at http://www.prweb.com/releases/2007/02/prweb502660.htm

]]> http://www.prweb.com/releases/2007/02/prweb502660.htm Euroscreen and Cephalon Extend their Collaboration for GPCR Drug Discovery http://www.prweb.com/releases/2007/02/prweb500845.htm Euroscreen s.a. announced that it has extended the term of an agreement with Cephalon, Inc. (Nasdaq: CEPH) to collaborate on multiple drug discovery programs through 2009. (PRWeb Feb 2, 2007)

Read the full story at http://www.prweb.com/releases/2007/02/prweb500845.htm

]]> http://www.prweb.com/releases/2007/02/prweb500845.htm Euroscreen Products SA Acquired By PerkinElmer Inc. http://www.prweb.com/releases/2007/01/prweb496527.htm Euroscreen SA focuses on Drug DiscoveryEuroscreen SA, a provider of GPCR products and services to the life sciences industry, today announced that they have completed a transaction with PerkinElmer Inc. (NYSE: PKI) to sell its Euroscreen Products sa subsidiary comprising all of Euroscreen's former GPCR products in exchange for €14 million in cash. Euroscreen retains its rights to the use of all Euroscreen Products' GPCR cell lines, membranes and AequoScreen™ technology for future use in its research and custom services businesses. (PRWeb Jan 12, 2007)

Read the full story at http://www.prweb.com/releases/2007/01/prweb496527.htm

]]> http://www.prweb.com/releases/2007/01/prweb496527.htm Euroscreen Files a CCR5 Patent Complaint Against Ono Pharmaceutical Co., Ltd http://www.prweb.com/releases/2006/08/prweb422382.htm Euroscreen s.a. announced today that it filed a complaint in the Osaka District Court (case number H18 (wa) 7760) alleging that Ono Pharmaceuticals Co., Ltd. infringed a basic CCR5 patent (JP Patent No. 3288384) in the discovery of Ono's CCR5 drug candidates. Ono has partnered these candidates with GSK. (PRWeb Aug 10, 2006)

Read the full story at http://www.prweb.com/releases/2006/08/prweb422382.htm

]]> http://www.prweb.com/releases/2006/08/prweb422382.htm Euroscreen Awarded U.S. Patent on Human Nociceptin (ORL1) Receptor http://www.prweb.com/releases/2006/08/prweb422384.htm Euroscreen SA today announced that it has been issued an U.S. patent that covers the use of an important human neurology drug target. The receptor, a G-protein-coupled receptor (GPCR) known as the human nociceptin (ORL1) receptor, is implicated in the control of some key neurological processes, such as pain perception, analgesia, and anxiety. Euroscreen’s patent protects any screening process using this receptor in order to find compounds that modulate its activity, and thus may have pharmaceutical potential. (PRWeb Aug 10, 2006)

Read the full story at http://www.prweb.com/releases/2006/08/prweb422384.htm

]]> http://www.prweb.com/releases/2006/08/prweb422384.htm Euroscreen Receives Key Patent for Purinergic Receptor http://www.prweb.com/releases/2006/05/prweb384934.htm Euroscreen SA today announced that it was awarded a US patent that covers the use of a G-protein-coupled receptor (GPCR) known as the human P2Y11 receptor. Euroscreen’s patent protects the sequence of P2Y11 receptor and research tools comprising this sequence. (PRWeb May 16, 2006)

Read the full story at http://www.prweb.com/releases/2006/05/prweb384934.htm

]]> http://www.prweb.com/releases/2006/05/prweb384934.htm Euroscreen Appoints Jean Combalbert, Ph.D., as CEO http://www.prweb.com/releases/2006/03/prweb359272.htm Euroscreen SA announced the appointment of Jean Combalbert, Ph.D. to the position of President & Chief Executive Officer. Dr. Combalbert joins Euroscreen with more than 15 years experience in pharmaceutical and biotech companies. (PRWeb Mar 17, 2006)

Read the full story at http://www.prweb.com/releases/2006/03/prweb359272.htm

]]> http://www.prweb.com/releases/2006/03/prweb359272.htm Institute Pasteur Korea and Euroscreen Form Strategic Alliance for GPCR Drug Discovery http://www.prweb.com/releases/2006/02/prweb351495.htm The Institute Pasteur Korea (IPK) and Euroscreen s.a. today announced a partnership to perform screening of G protein coupled receptors using internalization assays. The development at the Institute Pasteur Korea of a visual-based High Throughput Screening platform offers unique opportunities for the identification of drug candidates activating receptor internalization while Euroscreen’s receptor cell lines and GPCR library compounds will provide the initial direction and components for this drug discovery collaboration. (PRWeb Feb 27, 2006)

Read the full story at http://www.prweb.com/releases/2006/02/prweb351495.htm

]]> http://www.prweb.com/releases/2006/02/prweb351495.htm PharmaDesign and Euroscreen Form Strategic Alliance for GPCR Deorphanization http://www.prweb.com/releases/2006/01/prweb325484.htm PharmaDesign, Inc. and Euroscreen s.a. today announced a partnership to identify novel natural peptide ligands for orphan human G protein coupled receptors. PharmaDesign’s proprietary peptide library offers novel opportunities for identification of novel natural ligands while Euroscreen’s expertise in GPCR target discovery, functional screening of orphan receptors and pharmacological characterization will provide rapid screening of PharmaDesign’s Library and subsequent target validation. The partnership will provide novel Targets for partnering with shared income for the companies. (PRWeb Jan 5, 2006)

Read the full story at http://www.prweb.com/releases/2006/01/prweb325484.htm

]]> http://www.prweb.com/releases/2006/01/prweb325484.htm European Patent Awarded for CCR5 Chemokine Receptor, a Crucial Target for Novel AIDS Therapy http://www.prweb.com/releases/2005/11/prweb310257.htm ICOS extends the Joint patent estate with Euroscreen in Europe (PRWeb Nov 15, 2005)

Read the full story at http://www.prweb.com/releases/2005/11/prweb310257.htm

]]> http://www.prweb.com/releases/2005/11/prweb310257.htm Euroscreen Strengthens its Patent Position in the Field of Inflammatory Targets http://www.prweb.com/releases/2005/11/prweb307166.htm European patent awarded for uses of Chemerin receptor and its natural ligand, both implicated in the control of physiological and pathological inflammatory reactions (PRWeb Nov 9, 2005)

Read the full story at http://www.prweb.com/releases/2005/11/prweb307166.htm

]]> http://www.prweb.com/releases/2005/11/prweb307166.htm Euroscreen Awarded US Patent on P2Y13 (GPR86) Receptor http://www.prweb.com/releases/2005/09/prweb283135.htm Euroscreen SA, today announced the issuance of a US patent which covers the use of a human G-protein-coupled receptor (GPCR) known as the human P2Y13. Euroscreen’s patent protects any screening process using this receptor in order to find compounds that modulate its activity, and thus may have pharmaceutical potential. (PRWeb Sep 20, 2005)

Read the full story at http://www.prweb.com/releases/2005/09/prweb283135.htm

]]> http://www.prweb.com/releases/2005/09/prweb283135.htm Euroscreen Awarded US Patent Covering Mutant Polypeptides of SHIP2, an Emerging Target for the Treatment of Type 2 Diabetes Mellitus http://www.prweb.com/releases/2005/08/prweb278243.htm Euroscreen SA, today announced the issuance of a US patent which protects specific mutants affected in the catalytic site of the human SHIP2 protein. These are mutant proteins of SH2 domain containing inositolphosphate5-Phosphatase type2 (SHIP2). (PRWeb Aug 31, 2005)

Read the full story at http://www.prweb.com/releases/2005/08/prweb278243.htm

]]> http://www.prweb.com/releases/2005/08/prweb278243.htm Euroscreen Receives US Patent Covering Antibodies Which Bind To Delta32 CCR5 Mutant Chemokine Receptor http://www.prweb.com/releases/2005/08/prweb269383.htm Euroscreen s.a., a world leader in G-protein-coupled receptors (GPCRs), today announced the issue of a key US patent (6,930,174) in the area of CCR5 and diagnostic applications. The patent claims antibodies which specifically bind to the human delta32 mutant of the chemokine receptor CCR5. (PRWeb Aug 16, 2005)

Read the full story at http://www.prweb.com/releases/2005/08/prweb269383.htm

]]> http://www.prweb.com/releases/2005/08/prweb269383.htm ChemDiv and Euroscreen Form Strategic Alliance for GPCR Drug Development http://www.prweb.com/releases/2005/07/prweb255983.htm ChemDiv, Inc. and Euroscreen s.a. today announced a partnership to discover and develop drug candidates targeting difficult-to-discover drug candidates for high value GPCR family chemokine targets. (PRWeb Jul 1, 2005)

Read the full story at http://www.prweb.com/releases/2005/07/prweb255983.htm

]]> http://www.prweb.com/releases/2005/07/prweb255983.htm Euroscreen Awarded US Patent Covering High-Throughput Screening Method Using Aequorin http://www.prweb.com/releases/2005/03/prweb220958.htm Euroscreen SA, a world leader in G-protein-coupled receptors (GPCRs), today announced the issue of a US patent which further protects its useful high-throughput screening platform called AequoScreen™. The claims are related to a widely used diagnostic and screening method of modulators for any GPCR, calcium-coupled channel or any other calcium–coupled protein. (PRWeb Mar 29, 2005)

Read the full story at http://www.prweb.com/releases/2005/03/prweb220958.htm

]]> http://www.prweb.com/releases/2005/03/prweb220958.htm Euroscreen Announces SHIP2 License with Wyeth http://www.prweb.com/releases/2005/01/prweb191585.htm Euroscreen s.a. has completed a license agreement with Wyeth for access to the Euroscreen’s SHIP2 patent rights. Financial details of the agreement were not disclosed. (PRWeb Jan 3, 2005)

Read the full story at http://www.prweb.com/releases/2005/01/prweb191585.htm

]]> http://www.prweb.com/releases/2005/01/prweb191585.htm Euroscreen Enters Collaboration with Cephalon, Inc. to Discover GPCR-Directed Small Molecule Products http://www.prweb.com/releases/2004/12/prweb190552.htm Euroscreen s.a. today announced a collaboration with Cephalon, Inc. to discover and develop small molecule therapeutics targeting G-Protein Coupled Receptors, or GPCR, a family of receptors that play a major role in cell signaling. The companies will apply Euroscreen’s AequoScreen™ proprietary functional assay technology in their efforts to generate novel small molecule leads across a broad range of GPCR targets. Under the terms of the agreement, Euroscreen will receive upfront and R& payments with the potential for additional payments for successful programs. Euroscreen retains the right to aspects of the program that are not pursued by Cephalon in this collaboration. (PRWeb Dec 22, 2004)

Read the full story at http://www.prweb.com/releases/2004/12/prweb190552.htm

]]> http://www.prweb.com/releases/2004/12/prweb190552.htm